有“药中茅台”之称的内地大型药厂恒瑞医药(01276.HK) 今日首日挂牌，开报57元，较上市价44.05元高出29.4%，其后盘中曾高见60.6元，半日收57.65元，较上市价44.05元高出30.9%，成交额39.19亿元。恒瑞医药A股(600276.SH) 半日收55.36元人民币，微跌0.07%。
花旗5月初发表报告，料恒瑞医药(600276.SH) 2024年至2027年收入复合增长率为21%，总药品销售额复合增长率为22%，料创新药业务收入复合增长率35%。 该行亦列出对恒瑞医药(600276.SH) 未来三年业绩预测：
分项│2025年预测│2026年预测│2027年预测
收入│354.93亿元│419.37亿元│493.27亿元
毛利│305.88亿元│363.53亿元│429.97亿元
营运溢利│103.44亿元│126.12亿元│149.3亿元
EBIT│99.36亿元│121.31亿元│143.65亿元
纯利│87.77亿元│106.77亿元│126.51亿元
毛利率│86.2%│86.7%│87.2%
净利润率│24.7%│25.5%│25.6%
以上货币单位均为人民币
---------------------------------
分项│2025年预测│2026年预测│2027年预测
收入│354.93亿元│419.37亿元│493.27亿元
-销售药品收入│319.73亿元│381.14亿元│451.84亿元
-->创新药收入│177.3亿元│240.04亿元│317.62亿元
-->仿制药收入│142.44亿元│141.1亿元│134.22亿元
-许可(Licensing)收入│32.37亿元│35.31亿元│38.42亿元
(wl/a)(港股报价延迟最少十五分钟。) (A股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.